The American Heart Association identifies the year’s most impactful scientific discoveries
DALLAS, December 31, 2019 — Scientific research is the cornerstone for medical care and innovations that have improved health and longer life for many. The American Heart Association, one of the top funders of heart- and stroke-related research worldwide, has compiled an annual list of major advances in heart disease and stroke science since 1996. Here are the biggest scientific victories achieved in 2019, grouped into 10 subject areas, as determined by the Association’s volunteer leadership.
“Numerous research findings in 2019 yielded critical new information that builds on our vast, existing knowledge of cardiovascular disease – unfortunately, the leading cause of death worldwide. Scientific research and discovery are essential to improving our understanding of the intricacies of how the heart supports, impacts and interacts with every other part of the body, thus improving health outcomes and reducing deaths due to cardiovascular disease,” said Mariell Jessup, M.D., the Association’s chief science and medical officer. “We are proud that since our founding in 1949, the American Heart Association has invested more than $4.5 billion – we are the largest funder of scientific research outside of the U.S. federal government. We remain steadfast in our commitment to innovations and advances through our various programs, including research funding and scientific publishing and education, that ultimately can lead to longer and healthier lives for millions.”
Understanding pulmonary hypertension
Pulmonary hypertension is a rare form of high blood pressure that occurs when vessels carrying blood from the heart to the lungs become hard and narrow. While this rare condition has recently become more common, new research this year has helped reveal how this disease works.
One study, published in the American Journal of Respiratory and Critical Care Medicine, found that pulmonary hypertension patients had lower than normal levels of a protein known as BMP9. Researchers also noted that low levels of BMP9 may be a potential mechanism by which some people genetically inherit the disease.
Another study, published in the Association’s journal Circulation, explained how a gene that provides protein production instructions known as BOLA3 plays a crucial role in the disease, opening the door for potential therapies in the future.
Statins help children with inherited cholesterol problem
Familial hypercholesterolemia is a condition where people are born with high levels of LDL cholesterol, which can cause heart attacks starting at an early age. A long-term study published in the New England Journal of Medicine examined if cholesterol-lowering statins help children with the condition. Researchers compared the cardiovascular outcomes over 20 years of 214 patients with familial hypercholesterolemia to their 156 parents and found that statin therapy beginning at a young age:
- reduced incidence of cardiovascular events from 26% to 1% at age 39, and,
- reduced death from cardiovascular causes from 7% to 1% at age 39.
Older women need physical activity – and even a little helps
Regular physical activity is key to improving heart health for people of all ages. Among older women, two studies found reducing sedentary time improved outcomes. A study in Circulation examined the effect of sedentary behavior in a group of women with an average age of 79.  It found reducing sedentary time by just one hour each day equated to a 26% lower risk of heart disease and a 12% lower risk of cardiovascular disease overall. Notably, the physical activity didn’t have to happen all at once – it could be accumulated throughout the day.
Another study, in JAMA Network Open, suggested women who engaged in light physical activity, such as gardening or walking, had a 42% lower risk of heart attack or coronary death than the least-active women. The average age of women in the study was also 79.
Refining the strategies for controlling blood pressure
The importance of keeping blood pressure within a normal range is well established, however, improved treatment options and recommendations are still needed. Research published in the European Heart Journal found that people who took their blood pressure medication at bedtime had a 45% lower risk of heart attack, stroke or other cardiovascular problem.
The benefits of lowering blood pressure might extend to the brain, according to research published in JAMA. In a study of people ages 50 and older with high blood pressure, lowering systolic blood pressure – the top number in a reading – to a target of less than 120 mm Hg lowered the risk of mild cognitive impairment, compared to lowering blood pressure to less than 140 mm Hg. Mild cognitive impairment is a risk factor for dementia, and while the study did not find a statistically important lowering of dementia rates, it didn’t show an increase. Fear of increased risk of dementia has been a factor in the debate about how aggressively blood pressure should be treated, the researchers noted.
Research with practice-changing results that can save lives
These six studies are leading to shifts in care that the Association’s selection committee called “momentous for our patients:”
- In December, the Food and Drug Administration approved the use of icosapent ethyl, a prescription form of the omega-3 fatty acid EPA (a fish oil derivative), to reduce the risk of cardiovascular events among adults with elevated triglyceride levels. The approval came on the heels of a study published in the New England Journal of Medicine that found icosapent ethyl reduced the risk of having or dying from a stroke or heart-related problem by 25% in people with high triglyceride levels who were taking statins.
- A STEMI heart attack happens after a coronary artery is completed blocked. It’s commonly treated with a procedure known as coronary angioplasty, or percutaneous coronary intervention, which involves inserting a thin tube to open the clogged artery. A study published in the New England Journal of Medicine found that when doctors cleared multiple arteries entirely, patients had a 32% lower risk of another heart attack, compared to the patients treated with only clearing the blocked artery that caused the heart attack.
- People with Type 2 diabetes may be treated with the medication dapagliflozin to lower blood sugar levels. In a New England Journal of Medicine study, researchers reported that dapagliflozin kept heart failure from worsening and also reduced the risk of death from overall cardiovascular causes.
- ‘Siri, do I have AFib?’ A smartwatch was able to warn about atrial fibrillation, a type of irregular heartbeat, according to a study published in the New England Journal of Medicine. The study, which involved about 419,000 Apple Watch users, found the device accurately detected the condition in more than one-third of the participants who received notifications of an irregular pulse.
- When someone has an ischemic stroke – the most common type, where a vessel supplying blood to the brain is blocked – fast treatment to inject the clot-busting medication alteplase is considered essential. Generally, it has been thought alteplase needed to be administered within 4-1/2 hours of the onset of stroke symptoms. However, a study in the New England Journal of Medicine suggests some patients might be helped even if they receive the medication up to 9 hours after symptoms begin.
- Aortic stenosis is a common and serious heart valve disease. Treatment options include surgery to replace the faulty valve or a minimally invasive approach called transcatheter aortic valve implantation or replacement, also known as TAVI or TAVR. In TAVR, a replacement valve is inserted via a thin tube and wedged in place above the old valve. Researchers published findings in the New England Journal of Medicine that showed people with severe aortic stenosis at low surgical risk who had TAVR had lower odds of stroke, rehospitalization and death, compared to those who had traditional surgery.
Dangers for kids and women after pregnancy
According to an analysis published in the Journal of the American College of Cardiology, children exposed to secondhand smoke from their parents were at a higher risk for atrial fibrillation (AFib), a type of irregular heartbeat. For every pack-a-day increase in parental smoking, their children were 18% more likely to develop AFib.
Gestational diabetes, diabetes that develops during pregnancy, might signal future health problems in African American women, according to a study published in the Association’s journal Circulation: Cardiovascular Imaging. Among women who reported a previous pregnancy complication, those who had gestational diabetes were most likely to have coronary artery disease visible on an angiogram. These women were also more likely to have Type 2 diabetes. A commentary on the study said that the findings, “highlight the importance of asking black women about their pregnancy history and incorporating such history into risk assessment and medical care, especially for those with history of gestational diabetes mellitus.”
Gene studies expand knowledge about CVD
Two human genome studies offered new insights into venous thromboembolism, or VTE, and peripheral artery disease, or PAD. VTE, a condition where blood clots start in the vein, affects 300,000 to 600,000 Americans each year. A study published in Nature Genetics examined DNA from more than 650,000 people and found 22 new regions of the human genome that correspond with VTE, a potentially fatal condition.
People with PAD experience a narrowing of the peripheral arteries serving the legs, stomach, arms and head, which can lead to infection and death of body tissue. In a Nature Medicine study, researchers who tested DNA from more than 637,000 people identified 18 new parts of the genetic code associated with PAD.
A new understanding of heart failure
Heart failure, when the heart does not pump as well as it should, affects more than 6 million Americans. Heart failure with preserved ejection fraction is a type of heart failure where the heart muscle contracts normally but the ventricles do not relax as they should. As published in Nature (and described in the same publication), researchers developed a model of the disease in mice that uncovered a previously unknown driver of heart failure with preserved ejection fraction. These findings could lead to new treatment options that can reduce symptoms and help people with this type of heart failure live longer.
Exploring options to treat congenital heart disease
Single-ventricle physiology results from a congenital heart defect. In children born with this syndrome, the pulmonary valve does not form correctly and is sealed, and/or the right ventricle is malformed, meaning blood is unable to flow from the heart into the pulmonary artery and on to the lungs for oxygen. A form of open-heart surgery known as the Fontan procedure – where the blood flow is rerouted directly to the lungs – is sometimes used to treat it. However, the Fontan procedure can lead to multiple complications including deterioration of cardiovascular efficiency, which is associated with a reduced tolerance for physical activities and exercise. The results of a clinical trial published in Circulation found that teenagers who received the Fontan procedure as infants saw improvements in exercise performance after taking the medication udenafil, compared to those who received a placebo.
Engineering T cells to fight heart damage
Cardiac fibrosis, or scarring, is associated with nearly all forms of heart disease. A mouse study in Nature suggests engineered T cells – a type of white blood cell that’s part of the immune system – could be used to treat and reduce scarring in the heart.
“The idea that cardiovascular disease, the first cause of death in the U.S. and worldwide, could be cured by instructing T cells to kill detrimental cells is revolutionary,” Dr. Chiara Giannarelli, a cardiologist at Mount Sinai School of Medicine in New York, told The Scientist, although she noted more research is needed before it could be used to treat people.
The Association receives funding primarily from individuals. Foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Michelle Kirkwood: 703-457-7838, firstname.lastname@example.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and strokeassociation.org
 Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. Yu, P. et. al. American Journal of Respiratory and Critical Care Medicine. Vol. 199, No. 7. April 01, 2019. DOI: 10.1164/rccm.201807-1236OC.
 BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. Yu, Q. et. al. Circulation 2019;139:2238–2255. DOI: 10.1161/CIRCULATIONAHA.118.0358892238.
 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. Luirink, I. et. al. New England Journal of Medicine 2019; 381:1547-1556. DOI: 10.1056/NEJMoa1816454.
 Sedentary Behavior and Cardiovascular Disease in Older Women. Bellettiere, J. et. al. Circulation 2019;139:1036–1046. DOI: 10.1161/CIRCULATIONAHA.118.035312.
 Association of Light Physical Activity Measured by Accelerometry and Incidence of Coronary Heart Disease and Cardiovascular Disease in Older Women. LaCroix, A. et. al. JAMA Network Open. 2019;2(3):e190419. DOI: 10.1001/jamanetworkopen.2019.0419.
 Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Hermida, R. et. al. European Heart Journal, ehz754. DOI: 10.1093/eurheartj/ehz754.
 Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. Williamson, J. et. al. JAMA. 2019;321(6):553–561. DOI: 10.1001/jama.2018.21442.
 Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt, D. et. al. New England Journal of Medicine 2019; 380:11-22. DOI: 10.1056/NEJMoa1812792.
 Complete Revascularization with Multivessel PCI for Myocardial Infarction. Mehta, S. et. al. New England Journal of Medicine 2019; 381:1411-1421. DOI: 10.1056/NEJMoa1907775.
 Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. McMurray, J. et. al. New England Journal of Medicine 2019; 381:1995-2008. DOI: 10.1056/NEJMoa1911303.
 Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. Perez, M. et. al. New England Journal of Medicine 2019; 381:1909-1917. DOI: 10.1056/NEJMoa1901183.
 Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. Ma, H. et. al. New England Journal of Medicine 2019; 380:1795-1803. DOI: 10.1056/NEJMoa1813046.
 Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. Mack, M. et. al. New England Journal of Medicine 2019; 380:1695-1705. DOI: 10.1056/NEJMoa1814052.
 Childhood Tobacco Smoke Exposure and Risk of Atrial Fibrillation in Adulthood. Marcus, G. et. al. Journal of the American College of Cardiology. October 2019: Vol. 74, No.13:1658-1664. DOI: 10.1016/j.jacc.2019.07.060.
 Relationship Between Pregnancy Complications and Subsequent Coronary Artery Disease Assessed by Coronary Computed Tomographic Angiography in Black Women. Wichmann, J.L., Takx, R.A.P. et. al. Circulation: Cardiovascular Imaging. Vol. 12, No. 7; 2019: 12:e008754. DOI: 10.1161/CIRCIMAGING.119.009439.
 Pregnancy History Is Imperative for Cardiovascular Risk Assessment in Black Women. Tweet, M.S. Circulation: Cardiovascular Imaging. Vol. 12, No. 7; 2019;12:e009439. DOI: 10.1161/CIRCIMAGING.118.008754.
 Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Klarin, D. et. al. Nature Genetics. 2019 November 1;51: 1574–1579. DOI:10.1038/s41588-019-0519-3.
 Genome-wide association study of peripheral artery disease in the Million Veteran Program. Concato, J. et. al. Nature Medicine. 2019 July; 25:1274–1279. DOI:10.1038/s41591-019-0492-5.
 Nitrosative stress drives heart failure with preserved ejection fraction. Hill, J.A. et. al. Nature. 2019 April; 568: 351–356. DOI: 10.1038/s41586-019-1100-z.
 Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial. Goldberg, D.J. et. al. Circulation. 17 Nov 2019. DOI: 10.1161/CIRCULATIONAHA.119.044352.
 Targeting cardiac fibrosis with engineered T cells. Epstein, J.A. et. al. Nature. 2019 Sep;573(7774):430-433. DOI: 10.1038/s41586-019-1546-z. Epub 2019 Sep 11.
 CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis. Emma Yasinski. The Scientist. September 11, 2019. Accessed online.